CREATIVE LIFE SCIENCE (Stock Code: 7837), a leading Taiwanese brand in microbiology solutions and biopharmaceutical support services, today held its pre-listing investor conference ahead of its official listing on the Taiwan Emerging Stock Market on May 28. Taishin Securities will serve as the recommending securities underwriter.
Chairman and General Manager Yueh-Hung Tsai stated that CREATIVE LIFE SCIENCE is committed to becoming a globally recognized biotechnology and pharmaceutical supply chain partner, further strengthening Taiwan’s position within the international biopharmaceutical ecosystem.
CREATIVE LIFE SCIENCE Chairman and General Manager Yueh-Hung Tsai led the management team at the company’s pre-listing investor conference ahead of its Emerging Stock Market debut on May 28.
(From left to right: CREATIVE LIFE SCIENCE Vice President Han-Yi Lin, CFO Yu-Chia Tsao, Founder Professor Wen-Cheng Tsai, Chairman and General Manager Yueh-Hung Tsai, Taishin Securities Chairman Chia-Hung Kuo, and PwC Taiwan CPA Shu-Chiung Chang.)
According to Tsai, CREATIVE LIFE SCIENCE’s future development strategy is built upon three key pillars.
First, the company will continue strengthening its leadership position within its core microbiology and biopharmaceutical support businesses, leveraging its established supply chain capabilities to help customers accelerate product launches and enhance market competitiveness.
Second, CREATIVE LIFE SCIENCE will continue expanding into regenerative medicine and advanced biomanufacturing. The company’s PIC/S GMP-designed facility within the Zhubei Biomedical Science Park is scheduled for completion this year and is expected to support collaborations with leading domestic and international partners.
Third, the company plans to further strengthen industry collaboration and ecosystem integration through strategic partnerships, investments, and potential mergers and acquisitions, connecting upstream and downstream resources across the biotechnology and pharmaceutical industries.
Founded more than 45 years ago, CREATIVE LIFE SCIENCE has established itself as one of Taiwan’s leading microbiology brands and operates one of the country’s largest microbiology distribution networks. The company serves a broad customer base across pharmaceutical manufacturers, third-party testing laboratories, clinical diagnostic institutions, and food manufacturers.
To date, CREATIVE LIFE SCIENCE has developed more than 600 proprietary products aligned with international standards and compliant with ISO 13485 and QMS (GMP) requirements. The company continues to collaborate closely with academic and research institutions to develop innovative solutions that support customers throughout the product development and commercialization process.
Looking ahead, Tsai stated that CREATIVE LIFE SCIENCE expects to maintain double-digit revenue growth in 2025, driven by continued expansion in its core businesses and strategic investment returns. The company also plans to further strengthen international collaborations and continue building a broader biotechnology and pharmaceutical ecosystem through long-term strategic partnerships and resource integration initiatives.
